NASDAQ-NMS:IONS

Ionis Publishes 2023 Corporate Responsibility Report

Retrieved on: 
Jeudi, avril 25, 2024
DEI, Corporation, LEED, Education, IONS, Amyloidosis, Materiality, Certification, AFL, Ionis Pharmaceuticals, Vitamin A, STEM, Culture, Engineering, Environment, Science, Patient, Corporate social responsibility, DSM-IV codes, Caregiver, Serum, Gold, Polyneuropathy, Vitamin A deficiency, Corporate responsibility, Pharmaceutical industry

Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseases

Key Points: 
  • Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseases
    CARLSBAD, Calif., April 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future .
  • The report details Ionis' relentless passion to create better futures for people touched by serious disease as well as other stakeholders.
  • In 2023, Ionis extended its commitment to corporate responsibility (CR) through the establishment of three strategic pillars with actionable goals.
  • For more information on the 2023 Corporate Responsibility program, please visit: https://www.ionispharma.com/about/corporate-responsibility/
    For more information about QALSODY, visit https://www.qalsody.com/ .

Ionis to hold first quarter 2024 financial results webcast

Retrieved on: 
Mardi, avril 23, 2024
Webcast, Ionis Pharmaceuticals, IONS

CARLSBAD, Calif., April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.

Key Points: 
  • Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time
    CARLSBAD, Calif., April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
  • The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events .
  • A replay will be available for a limited time at the same address.

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Retrieved on: 
Dimanche, avril 7, 2024
TGS, AP, Ionis, Incidence, Abdominal pain, IONS, Webcast, Patient, NEJM, Fasting, American College, Ionis Pharmaceuticals, FCS, ACC, Triglyceride, Annual general meeting, Medicine, Pharmaceutical industry

CARLSBAD, Calif., April 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels. Importantly, olezarsen reduced the incidence of acute pancreatitis (AP) events over the 12-month treatment period compared to placebo. Olezarsen also demonstrated a favorable safety and tolerability profile. These results were presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published simultaneously in The New England Journal of Medicine (NEJM). Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.

Key Points: 
  • Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.
  • In the study, patients were treated with olezarsen 80 mg (n=22), 50 mg (n=21) or placebo (n=23) once every four weeks.
  • Serious AEs occurred in 14% of patients treated with olezarsen 80 mg, 19% treated with olezarsen 50 mg, and 39% treated with placebo.
  • Ionis will host a webcast to discuss the detailed results from the Balance study on Monday, April 8 at 10:00 am ET.

Ionis to present at upcoming investor conferences

Retrieved on: 
Lundi, avril 1, 2024
IONS, Conference, Ionis Pharmaceuticals, Pet industry

CARLSBAD, Calif., April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
    23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024
    2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024
    BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024
    45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024
    A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events .
  • Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

Ionis to hold olezarsen Phase 3 data webcast

Retrieved on: 
Jeudi, mars 28, 2024
Webcast, IONS, Cardiology, FCS, Patient, American College, Ionis Pharmaceuticals

CARLSBAD, Calif., March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.

Key Points: 
  • Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time
    CARLSBAD, Calif., March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.
  • The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events .
  • A replay will be available for a limited time at the same address.

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Retrieved on: 
Jeudi, février 29, 2024
Allergy, Schering-Plough, FCS, AstraZeneca, King Pharmaceuticals, EVP, Hereditary angioedema, Ionis Pharmaceuticals, Acorda Therapeutics, Human, Therapy, IONS, Patient, Neurology, Pharmaceutical industry

CARLSBAD, Calif., Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company. Mr. Jenne has more than 25 years of biopharmaceutical commercial and executive leadership experience and has launched innovative medicines across a broad range of therapeutic areas including cardiovascular, neurology and allergy.

Key Points: 
  • Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.
  • She has built a stellar team of professionals with deep experience across all aspects of commercialization," said Brett P. Monia, Ionis' chief executive officer.
  • Mr. Jenne previously spent five years in commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020.
  • His most recent role at Ionis was as EVP & chief commercial officer.

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Retrieved on: 
Jeudi, février 8, 2024
Ionis Pharmaceuticals, RNA, Cardiovascular disease, Therapy, Fast Track, Patient, FDA, Orphan, Amyloidosis, IONS, AstraZeneca, Food, Ionis, ATTR, Polyneuropathy, DSM-IV codes, Pharmaceutical industry

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.

Key Points: 
  • CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.
  • The FDA grants development programs Fast Track designation to facilitate the development and expedite the review of drugs that demonstrate the potential to treat serious conditions and fill an unmet medical need.
  • "CARDIO-TTRansform is the largest, most comprehensive study ever conducted in ATTR-CM patients, with results expected as early as next year."
  • WAINUA was granted Orphan Drug Designation in the U.S. and in the EU for the treatment of transthyretin-mediated amyloidosis (ATTR).

Ionis to hold fourth quarter and full year 2023 financial results webcast

Retrieved on: 
Mercredi, février 7, 2024
IONS, Ionis Pharmaceuticals, Webcast

CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.

Key Points: 
  • Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time
    CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.
  • The live webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events .
  • A replay will be available for a limited time at the same address.

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

Retrieved on: 
Jeudi, décembre 21, 2023
Quality of life, LICA, Food, AstraZeneca, Caregiver, Ionis Pharmaceuticals, FDA, Amyloidosis, Disease, ATTR, Serum, Polyneuropathy, Death, American Medical Association, Disability studies, TTR, JAMA, Patient, Diagnosis, IONS, Medicine, Journal, Heart failure, Neurology, Pharmaceutical industry

WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.

Key Points: 
  • WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.
  • "Approval of WAINUA represents a meaningful advancement in treatment, one that gives those who are living with transthyretin-mediated amyloid polyneuropathy help managing the disease."
  • WAINUA is a ligand-conjugated antisense oligonucleotide (LICA) medicine designed to reduce the production of TTR protein at its source.
  • "There is an urgent medical need for new therapies for people living with hereditary transthyretin-mediated amyloid polyneuropathy," said Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit, AstraZeneca.

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Retrieved on: 
Lundi, décembre 18, 2023
RNA, Hereditary angioedema, Ionis Pharmaceuticals, Orphan, ADPKD, HAE, Patient, IONS, OLE, Pharmaceutical industry

Ionis plans to independently bring donidalorsen to U.S. patients if approved

Key Points: 
  • Ionis plans to independently bring donidalorsen to U.S. patients if approved
    CARLSBAD, Calif., Dec. 18, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).
  • Ionis will maintain responsibility for the non-clinical and clinical development of donidalorsen, and Otsuka will be responsible for European regulatory filings and commercialization.
  • Ionis plans to independently launch donidalorsen in the U.S. if approved, as part of the company's strategy to deliver a steady flow of wholly owned medicines to patients.
  • The company plans to report Phase 3 results with donidalorsen for prophylactic treatment of HAE in the first half of 2024.